Researchers from the Center for Regenerative Medicine at Boston University (BU) and Boston Medical Center have announced a new collaboration with the global biopharma company GSK to advance innovative research focused on developing cutting-edge models to study and treat lung diseases like pulmonary fibrosis.
Pulmonary fibrosis, including its most common form, idiopathic pulmonary fibrosis, is a progressive and life-threatening condition that results in scarring of the lungs, making it increasingly difficult for patients to breathe. While the causes of this disease are complex and not fully understood, lung epithelial cells—specifically those lining the tiny air sacs where oxygen exchange occurs—have been found to play a central role in its development.
Together with GSK, the Boston-based research team will focus on understanding how dysfunctional lung epithelial cells initiate and perpetuate the disease, including alveolar type 2 cells, which are responsible for maintaining the lung’s delicate architecture…
Read the full article here.
